<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The Barrett's multistage process is characterized histopathologically by progression from Barrett's <z:mpath ids='MPATH_167'>intestinal metaplasia</z:mpath> to <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> with <z:mpath ids='MPATH_589'>dysplasia</z:mpath> and ultimately <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>Understanding of the molecular alterations in this multistage process may contribute to improved diagnosis and treatment </plain></SENT>
<SENT sid="2" pm="."><plain><z:chebi fb="0" ids="26537">Retinoid</z:chebi> X receptors (RXR) play an important role in regulating the morphogenesis, development, growth, and differentiation of cells </plain></SENT>
<SENT sid="3" pm="."><plain>Alterations in RXR expression have been observed in a variety of <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid tumors</z:e>; however, the role in <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> disease has yet to be determined </plain></SENT>
<SENT sid="4" pm="."><plain>The aim of this study was to assess the prevalence and timing of RXR <z:chebi fb="5" ids="33699">messenger RNA</z:chebi> expression in the Barrett's <z:mpath ids='MPATH_160'>metaplasia</z:mpath>-<z:mpath ids='MPATH_589'>dysplasia</z:mpath>-<z:mp ids='MP_0009308'>adenocarcinoma</z:mp> sequence and to investigate its role in the development and progression of this disease </plain></SENT>
<SENT sid="5" pm="."><plain>We analyzed the <z:chebi fb="2" ids="33699">mRNA</z:chebi> expression of <z:hpo ids='HP_0000001'>all</z:hpo> three RXR subtypes (RXR-alpha, RXR-beta, and RXR-gamma) by using a quantitative real-time reverse transcription-polymerase chain reaction method in 108 specimens from 19 patients with <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> without <z:mp ids='MP_0002038'>carcinoma</z:mp> (BE group), 20 patients with Barrett's-associated <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> (EA group), and a control group of 10 patients without evidence of <z:hpo ids='HP_0002020'>gastroesophageal reflux disease</z:hpo> (CG) </plain></SENT>
<SENT sid="6" pm="."><plain>RXR-alpha <z:chebi fb="2" ids="33699">mRNA</z:chebi> expression was significantly decreased (P &lt; 0.001; Kruskal-Wallis test), and RXR-gamma was significantly increased (P &lt; 0.001) at higher stages in <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> </plain></SENT>
<SENT sid="7" pm="."><plain>RXR-beta expression was highest in Barrett's tissues and was significantly increased compared to <z:mpath ids='MPATH_458'>normal</z:mpath> squamous tissues (P=0.01; Wilcoxon test) and <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> tissues (P=0.018, Mann-Whitney test) </plain></SENT>
<SENT sid="8" pm="."><plain>RXR-alpha and RXR-beta <z:chebi fb="2" ids="33699">mRNA</z:chebi> expression was significantly associated in <z:mpath ids='MPATH_458'>normal</z:mpath> squamous esophagus tissues (r(2)=0.49; P &lt; 0.001; Spearman test), Barrett's tissues (r(2)=0.63; P &lt; 0.001), and <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> tissues (r(2)=0.68; P=0.001) </plain></SENT>
<SENT sid="9" pm="."><plain>There were significant differences in RXR-alpha (P=0.011) and RXR-beta (P=0.005) <z:chebi fb="2" ids="33699">mRNA</z:chebi> expression in histopathologically <z:mpath ids='MPATH_458'>normal</z:mpath> squamous esophagus tissues in patients with <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> and the control group without evidence of <z:hpo ids='HP_0002020'>gastroesophageal reflux disease</z:hpo> </plain></SENT>
<SENT sid="10" pm="."><plain>These findings suggest that alterations in the <z:chebi fb="2" ids="33699">mRNA</z:chebi> expression of <z:hpo ids='HP_0000001'>all</z:hpo> three RXR subtypes are frequent events in the development and progression of <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> and associated <z:mp ids='MP_0009308'>adenocarcinoma</z:mp>, that RXR <z:chebi fb="2" ids="33699">mRNA</z:chebi> expression levels may be useful biomarkers for this disease, and that a widespread "field-effect" is present in the <z:mpath ids='MPATH_458'>normal</z:mpath> esophagus of patients with esophageal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> </plain></SENT>
</text></document>